Want to see INOD full AI Analyst Report?
Adjusted EBITDA by Segment
Provides a view of operating performance by segment, excluding non-cash items and one-time charges, to assess underlying profitability and cash flow potential.Innodata's DDS segment shows a dramatic surge in adjusted EBITDA, reflecting the company's strategic focus on generative AI and Agentic AI, which aligns with market demands. This growth is bolstered by significant new deals and a robust pipeline, as highlighted in the earnings call. Synodex and Agility segments also show positive momentum, contributing to the overall 375% increase in adjusted EBITDA. However, increased operating expenses and a higher future tax rate could pose challenges to net income. The company remains optimistic, raising its full-year revenue growth guidance to at least 45%.
Date | DDS | Synodex | Agility |
|---|---|---|---|
Dec 31, 2025 | $14.07M | $321.00K | $1.35M |
Sep 30, 2025 | $15.22M | $135.00K | $854.00K |
Jun 30, 2025 | $12.21M | $461.00K | $558.00K |
Mar 31, 2025 | $11.54M | $418.00K | $754.00K |
Dec 31, 2024 | $12.24M | $797.00K | $1.10M |
Sep 30, 2024 | $12.09M | $531.00K | $1.24M |
Jun 30, 2024 | $1.27M | $522.00K | $990.00K |
Mar 31, 2024 | $2.17M | $462.00K | $1.15M |
Dec 31, 2023 | $2.67M | $372.00K | $1.24M |
Sep 30, 2023 | $2.17M | $61.00K | $942.00K |